Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Símbolo de cotizaciónTTNP
Nombre de la empresaTitan Pharmaceuticals Inc
Fecha de salida a bolsaJan 18, 1996
Director ejecutivoMr. Weei Jye Chay
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 18
DirecciónSuite 505
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono14152444990
Sitio Webhttps://www.titanpharm.com/
Símbolo de cotizaciónTTNP
Fecha de salida a bolsaJan 18, 1996
Director ejecutivoMr. Weei Jye Chay
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos